Association of functional thrombin-activatable fibrinolysis inhibitor (TAFI) with conventional cardiovascular risk factors and its correlation with other hemostatic factors in a Spanish population

American Journal of Hematology

Volumn 76, Issue 4, 2004, Pages 348-352

  Santamaría, Amparo ^a,b   Borrell, Montserrat ^a   Oliver, Arturo ^a   Ortín, Rosa ^a   Forner, Ruth ^a   Coll, Inmaculada ^a   Mateo, Jose ^a   Souto, Juan Carlos ^a   Fontcuberta, Jordi ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Cardiovascular risk factors; Hemostatic factors; TAFI

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; PROTEIN C; PROTEIN S; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORRELATION FUNCTION; FEMALE; HEMOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; SPAIN;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD COAGULATION FACTORS; BLOOD PROTEINS; CARBOXYPEPTIDASE U; CARDIOVASCULAR DISEASES; COMORBIDITY; FEMALE; HEMOSTASIS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; SPAIN;

EID: 3342888062     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20108     Document Type: Article

References (17)

1. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an anti-fibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000;20:2511-2518.
2. Bouma BN, Marx PF, Mosnier LO, Meijers J. Thrombin-activatable fibrinolysis inhibitor. Thromb Res 2001;101:329-354.
3. Mosnier LO, von dem Borne P, Meijers J, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998;80:829-835.
4. Nesheim ME. TAFI. Fibrinolysis Proteolysis 1999;13:72-77.
5. Juhan-Vague I, Renucci JF, Grimaux M, et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol 2000;20:2156-2161.
6. Chetaille P, Alessi MC, Kouassi AD, Morange PE, Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb Haemost 2000;83:902-905.
7. Bouma BN, Mosnier LO, Meijers J, Griffin JH. Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation. Thromb Haemost 1999;82:1703-1708.
8. Mosnier LO, Elisen MG, Bouma BN, Meijers JC. Protein C inhibitor regulates the thrombin-thrombomodulin complex in the up- and downregulation of TAFI activation. Thromb Haemost 2001;1057-1064.
9. Mosnier LO, Meijers JC, Bouno BN. Regulation of fibrinolysis I plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001;85:5-11.
10. Mosnier LO, Meijers JC, Bouma BN. The role of protein S in the activation of thrombin activatable fibrinolysis inhibitor (TAFI) and the regulation of fibrinolysis. Thromb Haemost 2001;8:1040-1046.
11. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterised by a poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-1008.
12. Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE. Increased fibrinolytic activity during the use of oral contraceptives is induced by the estrogen component and counteracted by an enhanced factor XI independent down regulation of fibrinolysis. Thromb Haemost 2001;(Suppl 1):abstract P2984.
13. Arkel YS, Spratt D, Ku DH, et al. Increased thrombin generation as per endogenous thrombin potential (ETP), coagulation activation markers (TpP, TAT, and PF1.2), and TAFI levels in subjects treated with estrogens hormone replacement (HRT). Thromb Haemost 2001;(Suppl 1):abstract P3018.
14. Bittner V. Lipoprotein abnormalities related to women's health. Am J Cardiol 2002;90(8A):77i-84i.
15. Kuller LH, Women's Health Initiative. Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women's Health Initiative. Arterioscler Thromb Vasc Biol 2003;23:11-16.
16. Trégouet DA, Aubert H, Henry M, et al. Combined segregation-linkage analysis of plasma thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels with TAFI gene polymorphism. Hum Genet 2001;109:191-197.
17. Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001;97:2053-2058.